Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF COMMERCIAL OFFICER | April 07, 2026 | April 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
After 2026-04-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-07 · Exercise / conversion · Acquired 7,500 · Balance 7,500 |
| Common StockSEC Table I · non-derivative | Direct | 4,327 |
Reported balance
After 2026-04-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-04-07 · Tax withholding · Disposed 3,173 · Balance 4,327 F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,500 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 7,500 · Balance 7,500 F2: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date
F2: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 9, 2026 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002064712-26-000004 · form4-04092026_040401.xml · derivative · entry 3 Zaeske Adam H. · CIK 0002064712 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 3,173 | $27.62 | $87,638.26 |
DisclosureSEC source: 0002064712-26-000004 · form4-04092026_040401.xml · nonDerivative · entry 2 Zaeske Adam H. · CIK 0002064712 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,327 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002064712-26-000004 · form4-04092026_040401.xml · nonDerivative · entry 1 Zaeske Adam H. · CIK 0002064712 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 16,200 | $0.00 | $0.00 |
DisclosureSEC source: 0002064712-26-000002 · form4-01262026_090126.xml · derivative · entry 2 Zaeske Adam H. · CIK 0002064712 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 56,900 | $0.00 Strike: $36.76 | $0.00 |
DisclosureSEC source: 0002064712-26-000002 · form4-01262026_090126.xml · derivative · entry 1 Zaeske Adam H. · CIK 0002064712 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,900 Underlying: Common Stock · 56,900 shares Expires 2036-01-22 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| April 07, 2025 Filed Apr 16, 2025 20:06 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010798 · form4-04162025_080447.xml · derivative · entry 2 Zaeske Adam H. · CIK 0002064712 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on April 7, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| April 07, 2025 Filed Apr 16, 2025 20:06 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $28.40 | $0.00 |
DisclosureSEC source: 0001415889-25-010798 · form4-04162025_080447.xml · derivative · entry 1 Zaeske Adam H. · CIK 0002064712 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-07 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on April 7, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.